Hemenway Trust Co LLC Invests $323,000 in AstraZeneca PLC (NASDAQ:AZN)

Hemenway Trust Co LLC bought a new position in shares of AstraZeneca PLC (NASDAQ:AZN) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,770 shares of the company’s stock, valued at approximately $323,000.

Several other hedge funds also recently made changes to their positions in the business. Lindbrook Capital LLC boosted its position in shares of AstraZeneca by 1.7% during the 1st quarter. Lindbrook Capital LLC now owns 8,005 shares of the company’s stock worth $542,000 after acquiring an additional 137 shares in the last quarter. Beaird Harris Wealth Management LLC boosted its position in AstraZeneca by 8.9% in the fourth quarter. Beaird Harris Wealth Management LLC now owns 1,851 shares of the company’s stock valued at $125,000 after buying an additional 151 shares in the last quarter. Sage Mountain Advisors LLC boosted its position in AstraZeneca by 2.7% in the first quarter. Sage Mountain Advisors LLC now owns 6,017 shares of the company’s stock valued at $408,000 after buying an additional 158 shares in the last quarter. Bryn Mawr Capital Management LLC boosted its position in AstraZeneca by 0.3% in the fourth quarter. Bryn Mawr Capital Management LLC now owns 61,866 shares of the company’s stock valued at $4,167,000 after buying an additional 164 shares in the last quarter. Finally, Drive Wealth Management LLC boosted its position in AstraZeneca by 4.5% in the fourth quarter. Drive Wealth Management LLC now owns 3,911 shares of the company’s stock valued at $263,000 after buying an additional 170 shares in the last quarter. 20.35% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on AZN shares. The Goldman Sachs Group started coverage on shares of AstraZeneca in a report on Thursday, May 30th. They set a “buy” rating and a $97.00 price target on the stock. Barclays raised shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Citigroup raised shares of AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Finally, BMO Capital Markets lifted their price target on shares of AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday, April 26th. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, AstraZeneca has an average rating of “Buy” and an average target price of $88.00.

AstraZeneca Trading Up 0.2 %

AstraZeneca stock traded up $0.19 during trading hours on Thursday, reaching $77.94. The stock had a trading volume of 3,168,528 shares, compared to its average volume of 5,425,856. The stock has a market cap of $241.65 billion, a PE ratio of 38.21, a PEG ratio of 1.38 and a beta of 0.45. AstraZeneca PLC has a 52 week low of $60.47 and a 52 week high of $80.86. The company has a debt-to-equity ratio of 0.73, a current ratio of 0.89 and a quick ratio of 0.70. The company has a fifty day simple moving average of $78.11 and a 200-day simple moving average of $71.07.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, April 25th. The company reported $1.03 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.08. The firm had revenue of $12.68 billion for the quarter, compared to analyst estimates of $11.92 billion. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. Analysts forecast that AstraZeneca PLC will post 4.04 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.